Inhibition of PI3K signaling can inhibit tumor glycolysis by inhibiting release of aldolase from the cytoskeleton (Hu et al., 2016), suppressing membrane localization of glucose transporter 1 (Makinoshima et al., 2015), and by lowering the levels of c-Myc (Kalkat et al., 2017) and hypoxia-inducible factor 1 (HIF-1α) (Zhong et al., 2000), which drive expression of most of the glycolytic enzymes, including the A isoform of lactate dehydrogenase (LDHA) and hexokinase 2 (HK-II) (Dang et al., 2009). The gene discussed is PIK3CB; the disease is neoplasm.